Agnieszka Giza

Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial

Marek Trněný, Thierry Lamy, Jan Walewski et al. · The Lancet Oncology · 2016 · 155 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Oncology +8

Outcomes of treatment with dose‐adjusted EPOCH‐R or R‐CHOP in primary mediastinal large B‐cell lymphoma

Agata Malenda, Agnieszka Kołkowska‐Leśniak, Bartosz Puła et al. · European Journal Of Haematology · 2019 · 37 citations · Full text

Surgical Oncology, Pathology, Surgery +16

First‐line R‐CVP <i>versus</i> R‐CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4

Jan Walewski, Ewa Paszkiewicz‐Kozik, Wojciech Michalski et al. · British Journal of Haematology · 2019 · 25 citations · Full text

Type 2 diabetes mellitus compromises the survival of diffuse large B-cell lymphoma patients treated with (R)-CHOP – the PLRG report

Joanna Drozd‐Sokołowska, Jan Maciej Zaucha, Przemysław Biecek et al. · Scientific Reports · 2020 · 21 citations · Full text

Efficacy of radioimmunotherapy with (⁹⁰Y) ibritumomab tiuxetan is superior as consolidation in relapsed or refractory mantle cell lymphoma: Results of two phase II trials of the European MCL Network and the PLRG

Oliver Weigert, Wojciech Jurczak, Corinna Schilling et al. · Journal of Clinical Oncology · 2006 · 20 citations

Immunodeficiencies, Immunology, Pathology +19